| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Doyle Mittie is a Chief Medical Officer at AVTX. Recent filings cover 0 purchases and 17 sales. Those positions are worth an estimated $1.0M at current prices.
Doyle Mittie's largest disclosed position is in AVTX as Chief Medical Officer, worth about $1.0M. The recent filings there lean toward selling, a net 151,516 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | AVTX Avalo Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 679 | $16.00 | $10,864.00 | -15.8% | +10.7% | - | |
| Mar 16, 2026 | AVTX Avalo Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 25,492 | $16.15 | $411,606.58 | -87.6% | -8.9% | - |